Search clinical trials for: indacaterol/glycopyrrolate

Total 290 results

Merck Sharp & Dohme LLC

Completed

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Neuromuscular Blockade

United States, Austria, Belgium, Denmark, Finland, Germany, Spain, Turkey
Ziekenhuis Oost-Limburg
Merck Sharp & Dohme LLC

Completed

CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity (CURES)

Obesity | Surgical Conditions | Respiratory Function | Laparoscopic Gastric Bypass Surgery | Cerebral Tissue Oxygenation

Belgium
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
University of Utah

Enrolling by invitation

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Hyperhidrosis | Amputation

United States
Journey Medical Corporation

Completed

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Hyperhidrosis

United States, Germany
Pariser, Robert J., M.D.
Virginia Clinical Research, Inc.

Completed

An Open Label Study for Palmar Hyperhydrosis

Hyperhidrosis | Sweat Gland Diseases | Skin Diseases | Palmar Hyperhidrosis

United States
AstraZeneca

Recruiting

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (CHOROS ORION)

Chronic Obstructive Pulmonary Disease

Italy
Merck Sharp & Dohme LLC

Completed

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Reversal of Neuromuscular Blockade

United States, Austria, Denmark, Germany
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)

Anesthesia, General
Kokila N Thenuwara

Terminated

Minimizing Nausea and Vomiting During Spinals for CS

Nausea | Vomiting

United States
Thomas Jefferson University

Terminated

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G) (AIDES-G)

Depression | Hyperhydrosis

United States
Novartis Pharmaceuticals

Completed

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW3)

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom, Italy, United States, Romania
Icahn School of Medicine at Mount Sinai
NeuroVision

Completed

Intraoperative Video Laryngoscopy as Adjunct for Nerve Monitoring (IOVL)

Vocal Cord Function in Neck Procedures

United States
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) (EMERAL)

COPD

Mexico
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4)

COPD

Poland
Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide. (SYNERGY)

Chronic Obstructive Pulmonary Disease: COPD

Switzerland
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (EMERALD2)

COPD

Mexico
Hospital Clinic of Barcelona

Unknown

Pulmonary Gas Exchange Response to Indacaterol in COPD

Chronic Obstructive Pulmonary Disease

Spain
Dr. August Wolff GmbH & Co. KG Arzneimittel

Completed

Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Primary Axillary Hyperhidrosis

Germany
Novartis Pharmaceuticals

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Asthma

Spain, Hungary, United Kingdom, South Africa, Colombia, Bulgaria, Poland, Guatemala
Novartis Pharmaceuticals

Completed

Exacerbation Study (INVIGORATE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Colombia, Romania, South Africa, Italy, Hungary, Taiwan, Turkey, Switzerland, Australia, France, Israel, Sweden, China, Thailand, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Argentina, Lithuania, Austria, Cana... and more
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Chiesi Farmaceutici S.p.A.

Completed

Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers (Gly1)

Healthy

United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

COPD | COPD Exacerbation

United States, Bulgaria, Hungary, Poland, Argentina, Czechia, Mexico, Canada, Puerto Rico, Romania
Pearl Therapeutics, Inc.

Completed

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Dr. August Wolff GmbH & Co. KG Arzneimittel
Therapeutics, Inc.

Not yet recruiting

Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects With Primary Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Mayo Clinic

Recruiting

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Post-Dural Puncture Headache

United States
University of Kansas Medical Center

Completed

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

Burns

United States
Journey Medical Corporation

Completed

Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Chronic Obstructive Pulmonary Disease

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Neuromuscular Blockade

United States, Austria, Belgium, Denmark, Germany
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Novartis Pharmaceuticals

Completed

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Asthma

Germany, United States, Belgium, Latvia, Lithuania, Japan
Morten Hostrup, PhD

Recruiting

Role of Lung Function for Exercise Capacity in Well-trained Individuals

Exercise Performance

Denmark
Novartis Pharmaceuticals

Withdrawn

Efficacy of Indacaterol 150 µg Versus Formoterol

Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
Novartis Pharmaceuticals

Withdrawn

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (GLOW8)

Chronic Obstructive Pulmonary Disease
AstraZeneca
Iqvia Pty Ltd; Premier Inc.

Withdrawn

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US (IKANOS)

COPD

United States
Chiesi Farmaceutici S.p.A.

Completed

Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate

Pulmonary Disease, Chronic Obstructive

United Kingdom
Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Chronic Obstructive Pulmonary Disease

Hungary
Henry Ford Health System

Withdrawn

Residual Neuromuscular Blockade in Cardiac Surgery Patients

Residual Neuromuscular Blockade

United States

3

Subscribe